Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
by
Debord, Jean
, Robertsen, Ida
, Marquet, Pierre
, Woillard, Jean-Baptiste
, Åsberg, Anders
in
Cystic fibrosis
/ Datasets
/ Drug dosages
/ Health risk assessment
/ Inhibitor drugs
/ Internal Medicine
/ Medicine
/ Medicine & Public Health
/ Ordinary differential equations
/ Original Research Article
/ Pharmacokinetics
/ Pharmacology/Toxicology
/ Pharmacotherapy
/ Population
/ Studies
/ Transplants & implants
2018
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
by
Debord, Jean
, Robertsen, Ida
, Marquet, Pierre
, Woillard, Jean-Baptiste
, Åsberg, Anders
in
Cystic fibrosis
/ Datasets
/ Drug dosages
/ Health risk assessment
/ Inhibitor drugs
/ Internal Medicine
/ Medicine
/ Medicine & Public Health
/ Ordinary differential equations
/ Original Research Article
/ Pharmacokinetics
/ Pharmacology/Toxicology
/ Pharmacotherapy
/ Population
/ Studies
/ Transplants & implants
2018
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
by
Debord, Jean
, Robertsen, Ida
, Marquet, Pierre
, Woillard, Jean-Baptiste
, Åsberg, Anders
in
Cystic fibrosis
/ Datasets
/ Drug dosages
/ Health risk assessment
/ Inhibitor drugs
/ Internal Medicine
/ Medicine
/ Medicine & Public Health
/ Ordinary differential equations
/ Original Research Article
/ Pharmacokinetics
/ Pharmacology/Toxicology
/ Pharmacotherapy
/ Population
/ Studies
/ Transplants & implants
2018
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
Journal Article
A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
2018
Request Book From Autostore
and Choose the Collection Method
Overview
Background and Objective
Intracellular exposure of everolimus may be a better marker of therapeutic effect than trough whole blood concentrations. We aimed to develop pharmacokinetic population models and Bayesian estimators based on a limited sampling strategy for estimation of dose interval exposures of everolimus in whole blood and peripheral blood mononuclear cells (PBMCs) in renal transplant recipients.
Methods
Full whole blood and PBMC concentration–time profiles of everolimus were obtained from 12 stable renal transplant recipients on two different occasions, 4 weeks apart. The dataset was treated as 24 individual profiles and split into a development dataset (
n
= 20) and a validation dataset (
n
= 4). The pharmacokinetic model was developed using non-parametric modeling and its performances and those of the derived Bayesian estimator were evaluated in the validation set.
Results
A structural two-compartment model with first-order elimination and two absorption phases described by a sum of two gamma distributions were developed. None of the tested covariates (age, sex, albumin, hematocrit, fat-free mass and genetic variants such as
CYP3A5
*1,
ABCB1
haplotype,
PPARA
*42,
PPARA
*48, and
POR
*28) were retained in the final model. A limited sampling schedule of two whole blood samples at 0 and 1.5 h and one PBMC sample at 1.5 h post dose provided accurate estimates of the area under the plasma concentration–time curve (AUC) in comparison with the trapezoidal reference AUC (relative bias ± standard deviation = − 3.9 ± 10.6 and 4.1 ± 12.3% for whole blood and PBMC concentrations, respectively).
Conclusion
The developed model allows simultaneous and accurate prediction of everolimus exposure in whole blood and PBMCs, and supplies a base for a feasible exploration of the relationships between intracellular exposure and therapeutic effects in prospective trials.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
This website uses cookies to ensure you get the best experience on our website.